Second Systemic Sclerosis World Congress a Success PDF Print E-mail
Tuesday, 13 March 2012 14:09
Great success for the second Systemic Sclerosis World Congress that was held in February at the Palacio de Congresos de Madrid.

After the positive experience of 2010 in Florence, AIM Group International organised the second edition the congress, on behalf of World Scleroderma Foundation, founded by Alexander Klee, grandson of the great painter Paul Klee, who also a suffers from scleroderma, a so-called "rare" disease with very painful and debilitating effects.

To approach the social aspects of the disease, the Congress opened to the patients’ associations (FESCA - Scleroderma Federation of European Associations) and organized a parallel conference with hundreds of patients who had the opportunity to debate on clinical cases, experiences and opinions with experts and prominent international physicians.

With a qualified program consisting of seventy seven lectures, around sixty oral presentations and three hundred posters, the Congress attracted over 1,300 delegates from around the world: in fact, in addition to a prevalent presence from European countries, some hundred American, Asian and African participants contributed to reinforcing the international nature of the meeting.

At the end of the World Congress, the Scleroderma Foundation, chaired by Prof. Marco Matucci Cerinic, AIM Group International were appointed for the organisation of the next Congress, to be held in Paris in 2014.

Source: Agency & Association (2012), "The World Scleroderma Foundation meets in Madrid for the “Systemic Sclerosis World Congress” organised by AIM Group International"; ITCM

 
More articles :

» What Is Scleroderma?

DefinitionDerived from the Greek words “sklerosis,” meaning hardness, and “derma,” meaning skin, Scleroderma literally means hard skin. Although it is often referred to as if it were a single disease, Scleroderma is really a symptom of a...

» HLA Class II Haplotype and Autoantibody Associations in Children

L. R. Wedderburn; N. J. McHugh; H. Chinoy; R. G. Cooper; F. Salway; W. E. R. Ollier; L. J. McCann; H. Varsani; J. Dunphy; J.North; J. E. DavidsonPosted: 12/19/2007; Rheumatology. 2007;46(12):1786-1791. © 2007 Oxford University PressObjectives: To...

» UT Researchers At Forefront Of Efforts To Stem The Tide Of Autoimmune Diseases

Autoimmune and autoinflammatory diseases are on the rise and researchers and physicians at are at the forefront of efforts to stem the tide. These diseases are often hard to diagnose and often affect individuals differently.Autoimmune and...

» What's Your Scleroderma Action Plan?

Living with any serious disease or condition like Scleroderma, is without a doubt, difficult. It is not hard to understand either, that we often can lose sight of what is important, including our way. We may also fall into to a false sense of...

» The SCOT Study

SCOT is a clinical research study designed for people with severe forms of . SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation. The SCOT study will compare the potential benefits of stem cell transplant and high-dose monthly...

» Long-Term Outcomes of Scleroderma Renal Crisis

Virginia D. Steen, MD, and Thomas A. Medsger Jr., MDPublished: October 17th, 2000